GEP201706663B - Novel composition for nonalcoholic fatty liver disease (nafld - Google Patents
Novel composition for nonalcoholic fatty liver disease (nafldInfo
- Publication number
- GEP201706663B GEP201706663B GEAP201313941A GEAP2013013941A GEP201706663B GE P201706663 B GEP201706663 B GE P201706663B GE AP201313941 A GEAP201313941 A GE AP201313941A GE AP2013013941 A GEAP2013013941 A GE AP2013013941A GE P201706663 B GEP201706663 B GE P201706663B
- Authority
- GE
- Georgia
- Prior art keywords
- liver disease
- fatty liver
- nafld
- nonalcoholic fatty
- novel composition
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1468MU2013 IN2013MU01468A (OSRAM) | 2013-04-22 | 2013-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP201706663B true GEP201706663B (en) | 2017-05-10 |
Family
ID=49253372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201313941A GEP201706663B (en) | 2013-04-22 | 2013-06-25 | Novel composition for nonalcoholic fatty liver disease (nafld |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20160166539A1 (OSRAM) |
| EP (1) | EP2988736A1 (OSRAM) |
| JP (1) | JP6246895B2 (OSRAM) |
| KR (1) | KR101617812B1 (OSRAM) |
| CN (1) | CN105377246B (OSRAM) |
| AP (1) | AP2015008674A0 (OSRAM) |
| AU (1) | AU2013387996B2 (OSRAM) |
| BR (1) | BR112015020600A2 (OSRAM) |
| CA (1) | CA2900435C (OSRAM) |
| EA (1) | EA201592020A1 (OSRAM) |
| GE (1) | GEP201706663B (OSRAM) |
| HK (1) | HK1214968A1 (OSRAM) |
| IL (2) | IL240183A (OSRAM) |
| IN (1) | IN2013MU01468A (OSRAM) |
| MA (1) | MA38385A1 (OSRAM) |
| MX (1) | MX346943B (OSRAM) |
| MY (1) | MY180160A (OSRAM) |
| PH (1) | PH12015501795A1 (OSRAM) |
| SG (1) | SG11201506218UA (OSRAM) |
| UA (1) | UA114360C2 (OSRAM) |
| WO (1) | WO2014174524A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54735B1 (sr) | 2011-01-31 | 2016-10-31 | Cadila Healthcare Ltd | Tretman za lipodistrofiju |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| MA38385A1 (fr) | 2013-04-22 | 2017-09-29 | Cadila Healthcare Ltd | Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) |
| MX2015016403A (es) | 2013-05-30 | 2016-04-11 | Cadila Healthcare Ltd | Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica. |
| TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
| IN2013MU02470A (OSRAM) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| IN2013MU02905A (OSRAM) | 2013-09-06 | 2015-07-03 | Cadila Healthcare Ltd | |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| KR20180129909A (ko) * | 2016-04-22 | 2018-12-05 | 타이완제이 파마슈티컬스 컴퍼니 리미티드 | (비)알콜성 지방간염 또는 비알콜성 지방간 질환의 치료에 사용하기 위한 날메펜, 날트렉손 또는 이의 유도체 |
| EP3551180B1 (en) | 2016-12-09 | 2021-09-29 | Cadila Healthcare Limited | Treatment for primary biliary cholangitis |
| SI3600309T1 (sl) | 2017-03-28 | 2022-10-28 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| GB201710229D0 (en) | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
| WO2019071216A1 (en) * | 2017-10-06 | 2019-04-11 | Gilead Sciences, Inc. | POLYTHERAPY COMPRISING AN ACC INHIBITOR |
| CN109675016A (zh) * | 2017-10-18 | 2019-04-26 | 上海贺普药业股份有限公司 | 非酒精性脂肪性肝病的治疗药物 |
| CN110934866B (zh) * | 2018-09-25 | 2023-12-01 | 深圳微芯生物科技股份有限公司 | 西格列羧及其相关化合物的应用 |
| WO2020128815A1 (en) | 2018-12-18 | 2020-06-25 | Cadila Healthcare Limited | Saroglitazar for the treatment of hepatocellular carcinoma |
| WO2020165782A1 (en) * | 2019-02-13 | 2020-08-20 | Cadila Healthcare Limited | Treatment for polycystic ovarian syndrome (pcos) |
| EP4262776A1 (en) * | 2020-12-18 | 2023-10-25 | Société des Produits Nestlé S.A. | Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol |
| US20220378786A1 (en) * | 2021-05-21 | 2022-12-01 | HepQuant, LLC | Methods of defining functional change and slowing progression in chronic liver disease |
| WO2025238663A1 (en) * | 2024-05-16 | 2025-11-20 | Zydus Lifesciences Limited | Saroglitazar for the treatment of alcoholic liver diseases |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| PL174610B1 (pl) | 1992-07-03 | 1998-08-31 | Smithkline Beecham Plc | Nowe związki heterocykliczne |
| GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
| US5387613A (en) | 1993-07-23 | 1995-02-07 | Ribogene, Inc. | Treatment of tachyarrhythmias of supraventricular origin |
| GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
| WO1996004261A1 (en) | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes |
| CN1094940C (zh) | 1995-04-28 | 2002-11-27 | 第一制药株式会社 | 具有抗肿瘤活性的紫杉酚衍生物 |
| GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| US6130214A (en) | 1997-10-27 | 2000-10-10 | Dr. Reddy's Research Foundation | Benzothiazin and benzoxazin derivatives; their preparation and uses |
| DE69828445D1 (de) | 1998-04-23 | 2005-02-03 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
| CN100357281C (zh) | 1998-05-27 | 2007-12-26 | 雷迪实验室有限公司 | 双环化合物、其制备方法和包含它们的药物组合物 |
| EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000023445A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| WO2001053257A2 (en) | 2000-01-19 | 2001-07-26 | Cadila Healthcare Ltd. | Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| WO2002024625A2 (en) | 2000-09-22 | 2002-03-28 | Dr. Reddy's Research Foundation | Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| JP4261546B2 (ja) | 2003-09-26 | 2009-04-30 | 三菱レイヨン株式会社 | 電気泳動装置および電気泳動法 |
| UA85871C2 (uk) | 2004-03-15 | 2009-03-10 | Такеда Фармасьютікал Компані Лімітед | Інгібітори дипептидилпептидази |
| EP2388326A1 (en) * | 2005-09-19 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| KR20090083338A (ko) * | 2006-09-18 | 2009-08-03 | 알닐람 파마슈티칼스 인코포레이티드 | ＳＣＡＰ의 ＲＮＡｉ 조절 및 이들의 치료적 용도 |
| JP2008184429A (ja) * | 2007-01-30 | 2008-08-14 | Japan Health Science Foundation | 肝臓トリグリセリド濃度低下剤 |
| US8772342B2 (en) | 2009-11-26 | 2014-07-08 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| MX2013004123A (es) | 2010-10-12 | 2013-12-16 | Univ Johns Hopkins | Composiciones antitusigenas que comprenden memantina. |
| RS54735B1 (sr) * | 2011-01-31 | 2016-10-31 | Cadila Healthcare Ltd | Tretman za lipodistrofiju |
| MA38385A1 (fr) | 2013-04-22 | 2017-09-29 | Cadila Healthcare Ltd | Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) |
| MX2015016403A (es) | 2013-05-30 | 2016-04-11 | Cadila Healthcare Ltd | Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica. |
| TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
| IN2013MU02470A (OSRAM) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| IN2013MU02828A (OSRAM) | 2013-08-29 | 2015-07-03 | Cadila Healthcare Ltd | |
| IN2013MU02905A (OSRAM) | 2013-09-06 | 2015-07-03 | Cadila Healthcare Ltd |
-
2013
- 2013-06-25 MA MA38385A patent/MA38385A1/fr unknown
- 2013-06-25 WO PCT/IN2013/000391 patent/WO2014174524A1/en not_active Ceased
- 2013-06-25 MX MX2015010769A patent/MX346943B/es active IP Right Grant
- 2013-06-25 CA CA2900435A patent/CA2900435C/en not_active Expired - Fee Related
- 2013-06-25 IN IN1468MU2013 patent/IN2013MU01468A/en unknown
- 2013-06-25 KR KR1020157024370A patent/KR101617812B1/ko active Active
- 2013-06-25 HK HK16103017.5A patent/HK1214968A1/zh unknown
- 2013-06-25 GE GEAP201313941A patent/GEP201706663B/en unknown
- 2013-06-25 AP AP2015008674A patent/AP2015008674A0/xx unknown
- 2013-06-25 CN CN201380075905.9A patent/CN105377246B/zh active Active
- 2013-06-25 AU AU2013387996A patent/AU2013387996B2/en not_active Ceased
- 2013-06-25 UA UAA201509744A patent/UA114360C2/uk unknown
- 2013-06-25 US US14/782,609 patent/US20160166539A1/en not_active Abandoned
- 2013-06-25 BR BR112015020600A patent/BR112015020600A2/pt not_active IP Right Cessation
- 2013-06-25 JP JP2016505927A patent/JP6246895B2/ja active Active
- 2013-06-25 SG SG11201506218UA patent/SG11201506218UA/en unknown
- 2013-06-25 EP EP13767126.9A patent/EP2988736A1/en not_active Withdrawn
- 2013-06-25 MY MYPI2015002026A patent/MY180160A/en unknown
- 2013-06-25 EA EA201592020A patent/EA201592020A1/ru unknown
-
2015
- 2015-07-28 IL IL240183A patent/IL240183A/en not_active IP Right Cessation
- 2015-08-14 PH PH12015501795A patent/PH12015501795A1/en unknown
-
2016
- 2016-08-11 IL IL247231A patent/IL247231A/en not_active IP Right Cessation
- 2016-11-04 US US15/343,859 patent/US9814697B2/en active Active
-
2017
- 2017-11-02 US US15/801,738 patent/US20180185330A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170087127A1 (en) | 2017-03-30 |
| JP2016515608A (ja) | 2016-05-30 |
| EA201592020A1 (ru) | 2016-05-31 |
| IL240183A0 (en) | 2015-09-24 |
| HK1214968A1 (zh) | 2016-08-12 |
| EP2988736A1 (en) | 2016-03-02 |
| AU2013387996A1 (en) | 2015-09-24 |
| AU2013387996B2 (en) | 2015-12-10 |
| US20180185330A1 (en) | 2018-07-05 |
| PH12015501795A1 (en) | 2015-11-09 |
| JP6246895B2 (ja) | 2017-12-13 |
| UA114360C2 (uk) | 2017-05-25 |
| CA2900435C (en) | 2017-02-14 |
| MY180160A (en) | 2020-11-23 |
| US9814697B2 (en) | 2017-11-14 |
| WO2014174524A1 (en) | 2014-10-30 |
| MX2015010769A (es) | 2015-11-26 |
| IL247231A (en) | 2017-03-30 |
| MA38385A1 (fr) | 2017-09-29 |
| AP2015008674A0 (en) | 2015-08-31 |
| MX346943B (es) | 2017-04-06 |
| BR112015020600A2 (pt) | 2017-07-18 |
| CN105377246A (zh) | 2016-03-02 |
| CA2900435A1 (en) | 2014-10-30 |
| KR101617812B1 (ko) | 2016-05-03 |
| KR20150118990A (ko) | 2015-10-23 |
| WO2014174524A8 (en) | 2015-10-01 |
| IL240183A (en) | 2016-08-31 |
| IN2013MU01468A (OSRAM) | 2015-04-17 |
| CN105377246B (zh) | 2018-03-20 |
| US20160166539A1 (en) | 2016-06-16 |
| SG11201506218UA (en) | 2015-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP201706663B (en) | Novel composition for nonalcoholic fatty liver disease (nafld | |
| ZA202308496B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| NZ706739A (en) | Substituted benzene compounds | |
| MX2013011922A (es) | Compuestos de benceno substituido. | |
| IL234133B (en) | A medical preparation for the prevention and treatment of non-alcoholic fatty liver disease | |
| MX2019005082A (es) | Composiciones que comprenden 15-ohepa y metodos para usar las mismas. | |
| PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2012012095A (es) | Analogos de tiazolidinadiona. | |
| PH12017501122A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
| MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
| IN2014DN03010A (OSRAM) | ||
| EA201500737A1 (ru) | Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов | |
| ZA201606135B (en) | Pharmaceutical compositions of therapeutically active compounds |